Panitumumab in Japanese patients with unresectable colorectal cancer: A post-marketing surveillance study of 3085 patients

Narikazu Boku, Kenichi Sugihara, Yuko Kitagawa, Kiyohiko Hatake, Akihiko Gemma, Naoya Yamazaki, Kei Muro, Tetsuya Hamaguchi, Takayuki Yoshino, Ikuo Yana, Hiroshi Ueno, Atsushi Ohtsu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: Panitumumab was approved in Japan in April 2010 for the treatment of Kirsten rat sarcoma-2 virus oncogene wild-type unresectable and recurrent colorectal cancer. We conducted a post-marketing surveillance study to evaluate the safety and effectiveness of panitumumab. Methods: After panitumumab was commercially available in Japan, all patients to be treated with panitumumab were enrolled. Data on baseline characteristics, treatment outcome, and incidence and severity of adverse drug reactions were collected. Results: In total, 3091 patients were registered. In the safety analysis set (n = 3085), panitumumab was administered as monotherapy (40.7%) or combination therapy (59.4%). The median treatment duration was 113 days (range: 1-559 days), and 451 (14.6%) patients received panitumumab for ≥ 10 months. The overall incidence rate of adverse drug reactions was 84.1%, and the most common adverse drug reaction was skin disorders (78.4%). The incidence rates (all grades) of interstitial lung disease, infusion reaction, electrolyte abnormalities and cardiac disorders were 1.3% (mortality rate: 0.6%), 1.5, 19.3 and 0.2%, respectively. The median survival time of patients treated with panitumumab monotherapy as the third-line, or later, therapy was 10.3 months. Conclusion: This post-marketing survey in clinical practice confirmed the safety and effectiveness of panitumumab. The benefit/risk balance for panitumumab in Japanese patients with unresectable colorectal cancer remains favorable.

Original languageEnglish
Pages (from-to)214-223
Number of pages10
JournalJapanese journal of clinical oncology
Volume44
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1

Keywords

  • Colorectal cancer
  • Panitumumab
  • Post-marketing surveillance
  • Safety

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Panitumumab in Japanese patients with unresectable colorectal cancer: A post-marketing surveillance study of 3085 patients'. Together they form a unique fingerprint.

  • Cite this

    Boku, N., Sugihara, K., Kitagawa, Y., Hatake, K., Gemma, A., Yamazaki, N., Muro, K., Hamaguchi, T., Yoshino, T., Yana, I., Ueno, H., & Ohtsu, A. (2014). Panitumumab in Japanese patients with unresectable colorectal cancer: A post-marketing surveillance study of 3085 patients. Japanese journal of clinical oncology, 44(3), 214-223. https://doi.org/10.1093/jjco/hyt196